article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. The drug was originally developed by CV Therapeutics – bought by Gilead in 2009 – and first launched in the US in 2008.

article thumbnail

Astellas facing generics to big-selling Lexiscan product in US

pharmaphorum

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. It was first launched in the US in 2008.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Abilify generic availability, cost, and dosage

The Checkup by Singlecare

This is because generic medicines are much less expensive than their brand-name counterparts, even though they work just as well. What are the differences between brand name and generic Abilify? Aripiprazole was approved by the FDA in 2015. Aripiprazole is widely available at pharmacies across the U.S.

Dosage 52
article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

The last paracetamol plant in Europe, closed in France in 2008 as it was no longer economically sustainable, marking the exit of paracetamol manufacturing from Europe” The closure of API manufacturing plants in Europe started in earnest 15 years ago.